NasdaqHealth CareBiological Products, (No Diagnostic Substances)SOUTH SAN FRANCISCO, CA

Allogene Therapeutics, Inc. ALLO

Ask your AI

Estimated market cap $290.58M346.47M shares, shares as of Nov 3, 2026CIK 1737287

Insider trades, 12 mo

0 buys · 15 sells

$668.8K sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

129

55.0% of shares · 37 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Allogene Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 6, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Allogene Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

15 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Oct 21, 2026. Insiders have two business days to file.

Recent insider trades

Geoffrey M. Parker CHIEF FINANCIAL OFFICER	Oct 21 Form 4 ↗	Sale	−$48.7K 36,342 sh @ $1.34	-34.5%
Earl Martin Douglas SVP, General Counsel	Aug 21 Form 4 ↗	Sale	−$63.0K 29,697 sh @ $2.12	-58.4%
Annie Yoshiyama SVP, Finance	Apr 21 Form 4 ↗	Sale	−$22.1K 9,586 sh @ $2.31	-71.0%
Benjamin Machinas Beneski SVP, Chief Technical Officer	Mar 31 Form 4 ↗	Sale	−$7,168 2,867 sh @ $2.50	-81.6%
Benjamin Machinas Beneski SVP, Chief Technical Officer	Mar 16 Form 4 ↗	Sale	−$11.9K 4,835 sh @ $2.47	-78.4%

All ALLO insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

190.60M shares

129 funds report ALLO. Values checked against market prices.

Funds own 90% of shares (Q2 2026)

208 funds hold the stock.

Q3 2026: 55% · 5,560 of ~8,900 funds reported so far

Q2 202583%
Q3 202573%
Q4 202573%
Q1 202676%
Q2 202690%
Q3 2026 (so far)55%

Q3 2026. 16 new, 37 added to, 49 trimmed, 97 exited since Q2 2026.

Top 13F holders
#
1	BlackRock, Inc. 13F ↗	30.93M	$49.5M	+2.6%
2	Pfizer Inc 13F ↗	22.03M	$36.4M	unchanged
3	State Street Corp 13F ↗	16.33M	$26.1M	-14.2%
4	Primecap Management Co 13F ↗	13.15M	$21.0M	+0.2%
5	Vanguard Capital Management LLC 13F ↗	12.05M	$19.3M	-1.0%
6	UBS Group AG 13F ↗	10.70M	$17.1M	+252.3%
7	FMR LLC 13F ↗	10.60M	$17.0M	-11.7%
8	Marshall Wace, LLP 13F ↗	7.97M	$12.8M	+56.5%
9	Geode Capital Management, LLC 13F ↗	6.45M	$10.3M	-8.5%
10	Candriam S.C.A. 13F ↗	5.42M	$8.7M	+25.1%

Download CSV Every fund that holds ALLO, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Allogene Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Allogene Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

H-1B labor applications at Allogene Therapeutics, Inc.

1 certified in 12 mo

Labor condition applications decided by the Department of Labor, matched to Allogene Therapeutics, Inc. by employer name. An application is not a hire.

Median yearly wage offered, full-time certified applications, Jul 2025 to Jun 2026: —

H-1B labor applications decided at Allogene Therapeutics, Inc. by quarter
Quarter	Certified	All decided	Workers asked for
2024 Q3	0	0	0
2024 Q4	0	0	0
2025 Q1	0	0	0
2025 Q2	0	0	0
2025 Q3	0	0	0
2025 Q4	1	1	1
2026 Q1	0	0	0
2026 Q2	0	0	0

Most common job titles at Allogene Therapeutics, Inc.
Job title	Applications	Median wage
Senior Manager, Quality and Regulatory Systems	1	—

All ALLO applications

We match the employer's name to a public company automatically, including a reviewed list of subsidiaries. A subsidiary can be missed and a similar name can be matched wrongly. The files carry no worker names.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q1 2016	1	—	4,033	$115.0K
Q4 2018	79	+78	63.00M	$1.7B
Q1 2019	86	+7	65.69M	$1.9B
Q2 2019	94	+8	69.39M	$1.9B
Q3 2019	95	+1	90.08M	$2.5B
Q4 2019	116	+21	72.30M	$1.9B
Q1 2020	115	-1	73.76M	$1.4B
Q2 2020	173	+58	88.75M	$3.8B
Q3 2020	162	-11	85.25M	$3.2B
Q4 2020	165	+3	89.68M	$2.3B
Q1 2021	169	+4	88.37M	$3.1B
Q2 2021	182	+13	86.34M	$2.3B
Q3 2021	169	-13	87.97M	$2.3B
Q4 2021	177	+8	86.16M	$1.3B
Q1 2022	179	+2	91.81M	$837.3M
Q2 2022	160	-19	100.82M	$1.2B
Q3 2022	192	+32	106.29M	$1.1B
Q4 2022	168	-24	111.49M	$700.9M
Q1 2023	176	+8	119.24M	$589.1M
Q2 2023	171	-5	133.40M	$662.9M
Q3 2023	154	-17	130.30M	$413.1M
Q4 2023	170	+16	130.82M	$420.0M
Q1 2024	161	-9	140.87M	$629.2M
Q2 2024	175	+14	169.42M	$394.8M
Q3 2024	156	-19	168.46M	$471.8M
Q4 2024	174	+18	188.66M	$401.9M
Q1 2025	171	-3	197.16M	$301.8M
Q2 2025	160	-11	184.71M	$209.1M
Q3 2025	172	+12	163.11M	$202.3M
Q4 2025	173	+1	163.25M	$223.6M
Q1 2026	210	+37	184.58M	$445.7M
Q2 2026	209	-1	312.66M	$652.0M
Q3 2026	129	-80	190.60M	$306.0M

Each point is a quarter-end, from Q1 2016 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (019770106). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2016) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes14 in 12 mo 8-K events2 in 90 days Patents14 patents granted Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 15 in 12 mo Executive pay3 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials5 active IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Allogene Therapeutics, Inc.
Address: 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 457-2700
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Listed as: ALLO (Nasdaq)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$0.8387+$0.01 (+1.41%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.827 · High $1.34Nov 13, 2026

Aug 13, 2026Low $0.827 · High $2.23Nov 13, 2026

Nov 13, 2025Low $0.827 · High $3.06Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.